Amarin has fired its opening shot in the company’s appeal against Hikma winning a dismissal from a lower court against its allegations that the London-listed firm induced infringement of patents protecting a cardiovascular indication for Amarin’s Vascepa (icosapent ethyl) with its skinny-label generic.
While acknowledging that cases involving so-called skinny labels – generic medicines with patent-protected indications carved from their labels – can involve “difficult and close questions,” Amarin has argued before the US Court of Appeals for the Federal Circuit